Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model
Xin Wang,1,* Jin Deng,2,* Chongxiang Xiong,1 Haishan Chen,1 Qin Zhou,1 Yue Xia,1 Xiaofei Shao,1 Hequn Zou1 1Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 2Department of Nephrology, The First Affiliated Hospital...
Main Authors: | Wang X, Deng J, Xiong C, Chen H, Zhou Q, Xia Y, Shao X, Zou H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-06-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/treatment-with-a-ppar-gamma-agonist-protects-against-hyperuricemic-nep-peer-reviewed-article-DDDT |
Similar Items
-
Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats
by: Chongxiang Xiong, et al.
Published: (2021-02-01) -
Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy
by: Jing Pan, et al.
Published: (2019-01-01) -
GW9662, an antagonist of PPAR-gamma, inhibits breast tumour cell growth and promotes the anticancer effects of the PPAR-gamma agonist Rosiglitazone, independently of PPAR-gamma activation.
by: Gill, Jason H., et al.
Published: (2009) -
A novel heterozygous missense mutation in uromodulin gene in an Indian family with familial juvenile hyperuricemic nephropathy
by: D Saxena, et al.
Published: (2016-01-01) -
The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism
by: Raymond L. Konger, et al.
Published: (2019-06-01)